A Phase II, Single-Center, Randomized, Placebo-Controlled Study Evaluating the Therapeutic Efficacy of Intravenously Injected PEG-liposomal Prednisolone Sodium Phosphate (Nanocort) in Subjects with Severe Inflamed Carotid or Aortic Atherosclerosis Plaques.

Trial Profile

A Phase II, Single-Center, Randomized, Placebo-Controlled Study Evaluating the Therapeutic Efficacy of Intravenously Injected PEG-liposomal Prednisolone Sodium Phosphate (Nanocort) in Subjects with Severe Inflamed Carotid or Aortic Atherosclerosis Plaques.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Prednisolone (Primary)
  • Indications Atherosclerosis
  • Focus Therapeutic Use
  • Acronyms SILENCE
  • Most Recent Events

    • 01 Jul 2012 Actual end date (1 Dec 2012) added as reported by Netherlands Trial Register record.
    • 01 Jul 2012 Status changed from recruiting to completed as reported by Netherlands Trial Register record.
    • 18 May 2012 Planned end date changed from 1 Dec 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top